Molnupiravir for the treatment of Covid-19 patients. New launches in the Indian market are expected to drive domestic earnings with ~10 new product launches a year. The company has forayed into the agro-chemical business and invested in the Crop Health Sciences Division targeting niche products. Natco received final approval for Revlimed (Lenalidomide capsules) and...